SCHEMBL2909129

SCHEMBL2909129

CCOC(=O)c1ccc(NC(c2cccnc2)c2ccc(F)c(OC)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
GAA P10253 2/20 0.43
NAMPT P43490 2/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 7/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.42
PDE4D Q08499 1/20 0.42
MAPK1 P28482 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
USP2 O75604 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909625 0.91 TP53 (0.47) KMT2ANAMPTMAPTALDH1A1MEN1
SCHEMBL2905934 0.81 RCE1 (0.50) GAANAMPTPOLBALDH1A1PDE4D
SCHEMBL2910977 0.80 NAMPT (0.48) KMT2ANAMPTMAPTALDH1A1MEN1
SCHEMBL3202700 0.76 LMNA (0.40) KMT2AGAANAMPTMAPTALDH1A1
SCHEMBL2908503 0.75 RCE1 (0.50) KMT2AGAANAMPTPOLBMAPT
SCHEMBL3120604 0.74 F7 (0.44) KMT2AMAPTMEN1PDE4DMAPK1
SCHEMBL2909821 0.72 LMNA (0.45) GAAPOLBMAPTALDH1A1PDE4D
SCHEMBL2907869 0.72 PTGS2 (0.51) KMT2ANAMPTPOLBMAPTALDH1A1
SCHEMBL2909130 0.72 KMT2A (0.46) KMT2AGAANAMPTPOLBMAPT
SCHEMBL11066813 0.72 TBXAS1 (0.51) KMT2AGAANAMPTPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B KMT2A 1702/4885GAA 1294/4885NAMPT 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.